![Ultragenyx announces US FDA has granted orphan drug designation to UX701 for the treatment of Wilson Disease Ultragenyx announces US FDA has granted orphan drug designation to UX701 for the treatment of Wilson Disease](https://medicircle.in/uploads/2020/december2020/ultragenyx-announces-us-fda-has-granted-orphan-drug-designation-ux701-treatment-wilson-disease.jpg)
Ultragenyx announces US FDA has granted orphan drug designation to UX701 for the treatment of Wilson Disease
![Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease—Ultragenyx Pharmaceutical Inc. Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease—Ultragenyx Pharmaceutical Inc.](https://ir.ultragenyx.com/sites/g/files/knoqqb83881/themes/site/client_site/overwrite/wp-content/uploads/2022/12/Ultragenyx.Novato.03102022-4@2x.png)
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease—Ultragenyx Pharmaceutical Inc.
![Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver - The Lancet Gastroenterology & Hepatology Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/ecd0c0f5-6940-4bfc-b293-6caaea76c9b7/gr1_lrg.jpg)
Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver - The Lancet Gastroenterology & Hepatology
![Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease—Ultragenyx Pharmaceutical Inc. Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease—Ultragenyx Pharmaceutical Inc.](https://ir.ultragenyx.com/sites/g/files/knoqqb83881/themes/site/client_site/overwrite/wp-content/uploads/2023/02/Rare-Perspective-Mega-Menu.png)